Gazyvaro Targeting Tumor Promoting, Regulatory B cells in Solid Tumors
- Conditions
- •Melanoma: unresectable stage III with macroscopic lymph node, in transit/satellite metastasis or stage IV after = 2 lines of therapy (incl. checkpoint blockade, BRAF inhibitor)•Prostate carcinoma: castration-resistant, 2 lines of chemotherapy failed•CTCL: = stage IIB, = 2 previous lines of treatment
- Registration Number
- DRKS00017290
- Lead Sponsor
- niversität zu Köln
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting stopped after recruiting started
- Sex
- All
- Target Recruitment
- 1
•18 years of age or older
•Written, signed and dated informed consent before conduct of any study-specific procedure
•ECOG performance status of 0-2
•Life expectancy of more than 3 months
•Adequate organ function
oWBC = 2500/µL
oANC = 1000/µL
oPlatelets = 50 x 103/µL
oHemoglobin = 9 g/dL
oEstimated glomerular filtration rate > 30mL/min/1.73m2
oAST = 2.5 x ULN for patients without liver metastasis, = 5 x ULN for patients with liver metastasis
oBilirubin = 1.5 x ULN, (except patients with Gilbert’s Syndrome), Total bilirubin less than 3.0 mg/dL)
•Advanced disease:
•Prostate Cancer: Castration resistant metastatic disease, 2 prior lines of treatment have failed, known PSA serum level at baseline
•Melanoma: Unresectable stage III melanoma with N3 macroscopic lymph nodes or in-transit/satellite metastases or stage IV melanoma after standard therapy Known PD-L1, PD-1 and BRAF status at baseline level.
•CTCL: = stage IIB, = 2 previous lines of treatment (1 skin directed, 1 systemic); continuing skin directed therapy
•Measurable lesion according to RECIST 1.1/iRECIST/CTCL consensus criteria
•Recent biopsy confirming the diagnosis (< 4 weeks old)
•Reproductive Status
?Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception and must agree to use adequate method to avoid pregnancy for 7 month after the last dose of study drug.
?Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of ß-HCG) within one until two weeks prior to the start of obinutuzumab at time of neoadjuvant treatment and after surgery before starting adjuvant treatment.
?Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving atezolizumab and who are sexually active with WOCBP must be willing to adhere to contraception for a period of 7 month post treatment completion.
•Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
?Women <50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
•Women =50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
•Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to understand the patient information or complete the study
•Concurrent systemic immune therapy, ongoing chemotherapy or therapy with any anticancer drug not indicated in the study protocol
•Prior treatment with atezolizumab or obinutuzumab
•Any investigational agent(s) within 4 weeks prior to study entry
•Immuncheckpoint inhibitors, other immunomodulating agents or chemotherapy administered less than 4 weeks before first intake of stady drug
•Active or history of autoimmune disease that required systemic steroids or immunosuppressive medications, with exception of vitiligo or resolved childhood asthma
•New and active brain metastasis or meningeosis neoplastica. Note: Patients with stable or treated brain metastasis (e.g. after resection, intra or radiation therapy) are allowed to participate in this trial
•Ongoing necessity for systemic corticosteroids >10mg daily prednisone equivalent. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
•Active infection with HIV, HBV or HCV
•Active uncontrolled infection diseases
•Active tuberculosis
•History of another primary malignancy except for
Malignancy treated with curative intent and with no
known active disease =5 years before the first dose of IP
and of low potential risk for recurrence
?Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
?Adequately treated carcinoma in situ without evidence of disease
•History of active primary immunodeficiency
•Patients with severe cardiovascular disease (e.g. NYHA functional class III or IV, myocardial infarction within 6 months before inclusion, ventricular tachyarrhythmia requiring ongoing treatment, unstable angina pectoris)
•Treatment with immunosuppressive medications (including but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor) within 2 weeks prior to study entry
•Major surgery (defined as opening at least one body cavity) within 4 weeks prior to study entry
•History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening CT scan
•Prior allogeneic bone marrow transplantation or prior solid organ transplantation
•Pregnant or breastfeeding females
•Current treatment within another therapeutic clinical trial with experimental and not approved drugs and treatment combinations
•Allergies and Adverse Drug Reaction
?History of allergy to study drug components
?History of severe hypersensitivity reaction to any monoclonal antibody
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method